Trial Profile
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Avadomide (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 07 Apr 2020 Status changed from active, no longer recruiting to completed.
- 30 Jan 2020 Planned End Date changed from 9 Apr 2020 to 30 Mar 2020.
- 30 Jan 2020 Planned primary completion date changed from 9 Apr 2020 to 30 Mar 2020.